Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Information Commissioner urges people to share data to protect at-risk children
OpenAI's ChatGPT will 'see, hear and speak' in major update
GOP Effort to Curb ESG Fails to Yield Concrete Results So Far
Sarah Silverman sues OpenAI and Meta alleging copyright infringement
Apple TV’s Futuristic Climate Show Is Already Coming True
INFINIQ Launches AI-Data Service Platform ‘AI-Studio’ and AI-powered Video Search and Abnormal Behavior Monitoring Solution ‘HEIDI-ai MAX’
Kishida Meets Intel, TSMC, Micron Execs as Japan Joins Chip Race
The ‘Yield Curve’ Is Improving. These Types of Stocks Should Benefit.